The Specificity of the Microcytotoxicity Assay for cell-mediated Immunity in Human bladder Cancer

Publisher Website
Google Scholar
Abstract
Cytotoxicity of lymphocytes from T1 or T2 bladder cancer patients and patients with other diseases was tested in a 44 h microcytotoxicity assay against 3 different target cell lines: HU 456, derived from human bladder carcinoma; HU 609, a line derived from normal human bladder tissue; and SAOS-2, a human osteosarcoma cell line from the Memorial Sloan-Kettering Cancer Institute. Lymphocyte concentrations ranging 7.8 .times. 104 to 2.5 .times. 106 lymphocytes/ml were tested against each cell line. Lymphocytes from both groups of patients demonstrated a cytotoxicity against all 3 target cell lines, proportional to the lymphocyte concentration used. There was no difference in reactivity to HU 609 or to SAOS-2 between bladder cancer and control patients. The lymphocytes of bladder cancer patients showed a statistically greater cytotoxicity for HU 456, demonstrating a tumor type-specific cellular immune reaction superimposed on a background of non-specific cytotoxicity.